Amarin Corp PLC (AMRN) オプション

Thanks Capt. I guess to some degree it doesn't matter much since V is an approved drug and so forth. Not sure how much micro managing the head of the FDA would get involved in when it comes to the new formulation. I guess they have set rules they follow.

I find it interesting in a philosophical context that the FDA does not seem to get more involved with infringement. I mean they don't condone companies selling unapproved drugs, yet in a sense, for instance in our case, a drug is being sold that is not approved for the intended purposes many patients are taking it.
Oh well, just my frustration showing. Have a great weekend to you and the board.

Nuke ...If U accept the R-IT data , especially the AHA data that Capt just posted ....Vascepa is far more effective than Ezetimbe in reducing CV events ...at least in R-IT profile patients .
Ezetimbe ( Zetia ) is generic , cheap and a small pill ( if taken separately ) and is often added to low dose Statins if the patient needs to lower their LDL further but is complaining of new muscle aches etc on their current dose .
I took it for years ,,,but once I started taking Repatha with Crestor and Vascepa ....I dropped it . Repatha ( a PCSK9i ) and Crestor dramatically lower LDL cholesterol .
IIRC half in R-IT were on high intensity statin , mainly Lipitor and the other half on low intensity Simivastatin
Kiwi

I've tweeted dr McKary in the past about VASCEPA so, I'm pretty sure he is aware of it. 

Marty Makary to be next head of the FDA. Sounds like he wasn't the biggest fan of GLP-1 drugs. Hope he is aware of V, and is amenable to our new formulation, if it ever comes out.

You seem to be gaslighting yourself. Boilerplate language. RS is and always has been an option. If that was their priority, they had plenty of time to do it. Go back and reread the 8k, take as long as you like.  Report back when you find the word "open". 

What exactly is your frantic attempt of a question? AMRN now has 180 days to get pps over $1.00 for 10 trading days. Plenty of catalyst possibilities upcoming to help the cause. Your post makes a cup of coffee nervous

Now I might have a tough decision no thanks to the 8K. AMRN is open to the option of a R/S.

Spin me a tale but the investor basically loses, as after the R/S the pps falls again. Value is totally loss.

If someone can legitimately make a case for R/S to the investor's advantage, please do. I've only witnessed disaster. I mean this; An open invitation to anyone supporting a R/S. AMRN could buy back shares and be instantly compliant irrespective of the cash burn. I'd really like to read intelligent discussion between R/S and share BB.

Thank you friends.

IMO it's all relative to each individual condition & health problems. They do say however many review's say " According to study group results, a daily dose of atorvastatin 10 mg can decrease LDL cholesterol by 30%-40% while a daily dose of simvastatin 10 mg can decrease LDL cholesterol by 20%-30%., which is one of main attributes of the statins "to reduce cholesterol".
There be reasons why your physician ordered simvastatin versus atorvastatin?

Nuke, rmb: At my request, my PCP put me, via prescriptions, on both ezetimide and Vascepa. That was before I started mg ion per Dr. Dean's books discussed some weeks ago here. Suffice to say he was pleased with my latest blood sample test results. Information I have seen shows that number of  prescriptions for ezetimide are far greater than prescriptions for Vascepa, both in Europe and in United States. I had been prescribed simvastatin for many years prior to either of the other 2 drugs.
 

Come on, it's after 3pm on the West coast & past 6 on east coast. You don't expect that anyone is really watching or is aware of the release. We'll see what happens Monday at the earliest. Right now the news has not even been published on brokers trading sites i.e Etrade shows nothing.

Not everyone is constantly watching what AMRN does , like you do, every second it seems...

Interesting that there was a lot of after market volume yesterday as well as pre market volume this morning. But now, post the 180 day extension notice, next to no volume in the first 2 hours of the after market.

It's official.

BRIEF-Amarin Corp - Nasdaq Granted 180 Days To Regain Nasdaq Compliance
REUTERS 4:55 PM ET 11/22/2024
Symbol Last Price Change
AMRN 0.5486up +0.0237 (+4.5151%)
QUOTES AS OF 04:00:00 PM ET 11/22/2024
Nov 22 (Reuters) - Amarin Corporation PLC(AMRN):

* AMARIN CORP(AMRN) - NASDAQ GRANTED 180 DAYS TO REGAIN NASDAQ COMPLIANCE Source text: [https://tinyurl.com/bdhep7ek] Further company coverage:

The just filed 8-K: https://www.sec.gov/Archives/edgar/data/897448/000095017024130263/amrn-20241122.htm

If they were intent to reverse split they didn't need the extension. Good sign. I continue to think that between Italy, possibly China, possible Sarissa add, and initiation of buyback it can get back above $1 inside 6 months. The extra time also gets us past year end tax loss selling pressure.

Someone posted it..

180 day extension granted.

Same here

Amrn 8k filing email. I get a 404 error on it.

Nuke, not easy to give an ABC answer. First, one can say that medium intensity statins plus ezetimibe did show benefits over simply high intensity statins. But, this was a meta-analysis, and those are notorious since the authors decide what studies to pick and choose. Now the benefits over HIS by this combo was not as great as what Vascepa showed in R-I, BUT I can't find where there is a description of the statin used in R-I - whether it was Mid intensity or High intensity or low, but we do know that people were generally considered to having their cholesterol under control.

They have not cared to inform us about anything since they took over.

Thx Capt. https://www.ahajournals.org/doi/10.1161/circ.150.suppl_1.4140394

Clear separation in event lines by yr 2 . If you want to get reimbursement in Germany then run a small short trial with German patients to see if you can get the event lines separating as fast as they have by yr 2 in this abstract .

You only need about 1200 patients to try and reproduce these results
In patients without CAD, IPE demonstrated a 34% relative risk reduction in first (HR 0.66; 95% CI 0.51, 0.85; P=0.0012; NNT 13) and 47% reduction in total primary endpoint events (RR 0.53; 95% CI 0.40, 0.70;

NNT of 13 ?...47% reduction in total primary endpoint events ?

Good reminder to take my daily V :---)

Kiwi

Thanks Captain; Would someone please weigh-in on this ezetimibe study and compare it to icosapent ethyl? I know very little about interpreting Statistical Information, especially medical information. Is ezetimibe better or not? European Heart Journal article dated 28 October 2024.
https://academic.oup.com/eurheartj/article/45/Supplement_1/ehae666.3300/7839090

RMB, IDK about that particular settlement I didn't find anything in the public domain which includes a PBM. According to my research, I found HIKMA has several PBM's they deal with due to the insurance companies that distribute their GV. My response was more of a generic example of "what if".

https://www.fiercepharma.com/pharma/hikma-pharmaceuticals-accuses-adversary-amarin-keeping-lock-api-suppliers-preventing-generic

proliberty, Denner agreed with Biogen. He stepped down and appointed his girlfriend to his seat. See below.
Denner's personal life is a bit strained at the moment. LOL

https://www.biopharmadive.com/news/biogen-board-denner-langer-directors/652838/

Good luck MMS!
I have 150K shares @ average $1.88
Picked up a pile of Jan 1.00 calls (after not purchasing options for well over a year).
Hoping, but not counting on, a Festivus miracle for all longs.
Cheers!
RTV

Per the WhaleWisdom 13F summary below, Sarissa dumped Biogen (a long held mistake for them and formerly their largest position). Innoviva is now the largest position at 35%. Amarin about 3.9%. https://whalewisdom.com/filer/sarissa-capital-management-lp

Bought a small number of shares and averaged down to $2.55

Hate being a PIA, but is seems that understand what North is talking about wrt some sort of settlement (Hikma/PBM/Amarin).   Since I don't quite know about this (North has even alluded to him possibly making this up) and even JRoon was inquiring as to what North was referring to, could you elaborate for us in simple terms we can understand?   TIA

Capt
Thanks
Happy Thanksgiving have a cold one for me

North, I happened to watch the Carson Block interview earlier in the day on CNBC. His short thesis is about ELF's inventory games with China. Very interesting Muddy Waters is one of the best shortsellers in the street since I was on the same side many years ago I totally understand the depth of research necessary to be successful. Why would the company wait till Cramers show to explain the redactions. I didn't see that interview but I would be leary re their explanation.
Re the second question about publishing an unredacted settlement with HIKMA/PBM/AMRN. Only if it's beneficial to our company should they pursue that issue in court. Would it be wise or worth the legal expense to push the envelope only if it's to Amarin's benefit? IDK that answer.
Since amrn is hard to borrow I doubt any HF would still be short at this price, too risky, they would be exposed to a buy-in if the price shot up.

Its booming ! Major announcement coming. Greenland soon to approve vascepa !

Hi Monk,
Your friend has an interesting podcast, but I'm not sure if Dr. Bhatt would want to appear on a medical commercialization platform especially since he's a board member of BMS. He might have an interest if your friend's platform was pure research and not commercialization. However, Dr. Bhatt is on LinkedIn, X and probably others where your friend can reach out for an audience.

Giovinco, IIRC, at some point in the recent presentation Berg mentioned the company has requested a listing extension. So I guess it's been granted. Since they talked about that issue on the call the company isn't obligated to issue an 8K.

Captain
Please look at this link. #1 Medtech Podcast, Omar is a friend.
He said he would love to have Dr. Bhatt on. Can you help facilitate this and or see if he might be interested in being on Omar's show? My email is tekrz@comcast.net.
https://www.linkedin.com/in/okhateeb/?midToken=AQEit0aY-_rRZQ&midSig=0zQgibtXwKybw1&trk=eml-email_member_message_v2-one_to_one_single_thread-0-null&trkEmail=eml-email_member_message_v2-one_to_one_single_thread-0-null-null-d6sy2~m3s49lf5~26-null-null&eid=d6sy2-m3s49lf5-26&otpToken=MTAwNzFmZTUxMDJhY2NjY2JlMmYwMmU5NDQxY2UzYjY4ZWM5ZDg0MTlhYTg4NTY5NzFjNDAxNmM0ZDVlNWJmOTg0ZGM5MzkwNGNlMmZiZjAzMDIyYmFjMzJjZDkwOWVmMDliZDdmYThiNWYzMjllMiwxLDE%3D

$AMRN Results from AHA Abstract 4140394: Substantial cardiovascular risk reduction with icosapent ethyl in patients with prior cardiovascular events regardless of coronary artery disease history: REDUCE-IT CAD

Let me count the Ways! (Number 20) in a continuum of MOA’s for the pleiotropic benefits of VASCEPA®/VAZKEPA®.

CONCLUSION: IPE demonstrated robust CV benefit in statin-treated patients with CV disease. Patients with and without CAD experienced large reductions in absolute and relative risk of CV events.

Repeat after me…..”It’s the EPA Stupid!”

https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4140394

Allow for the possibility that an SEC filing of the settlement is in the works, but a leak of contents has occurred. Also allow for the possibility I made up the entire story that has confused you; I also may be erroneous in thinking that Centene is the parent of Hikma's PBM drug company.

The ELF story is real. ELF traded higher after hours Thursday evening. Let's see how it trades today. I own no shares of ELF.

I like the continuation of any unannounced FTC investigation of higher Vascepa scrip prices caused by collusive, deceptive practices of 2 generics in persuading the Nevada District to invalidate Amarin's 6 patents reflecting the results the Marine trial better anyway. 

frankly quite incredible there was no PR and no 8K about the extra 6 months they applied for confirming the 6 extra months beyond Nov 20, the new deadline is May 20 I guess, they didn't care to inform us

North, I'm confused. What settlement agreement are you referring to?

What might be the effect of a public letter to 1) Hikma's CEO, 2) CNC, 3) Sarissa Capital and Amarin's current CEO asking that the redacted portions of the settlement agreement between Hikma's PBM and Amarin be made public?

Lizzie, it seems that the "muddy waters" hedge fund put out a negative report earlier this week that relied on an SEC filing by ELF that contained a lot of redacted information. ELF dropped in price by ~ 33%.  The CEO of ELF appeared on CNBC-TV Thursday evening (~ 6:20-6:30 pm), and explained that the redactions contained information that belied/countered the negative thesis and misinformation in that report.  

What might be the effect of a public letter to 1) Hikma's CEO, 2) CNC, 3) Sarissa Capital and Amarin's current CEO asking that the redacted portions of the settlement agreement between Hikma's PBM and Amarin be made public? Would this letter be public enough to attract attention of other short/hedge  funds to cause them to cover their short positions? Would it matter whether the above entities answered this letter? 

Somewhat unusual pre market action with 55k trading with a vwap of $0.5254.

https://www.sciencedirect.com/science/article/abs/pii/S0924224424004758

So your bullish AMRN because INVA will take over AMRN for $2-4 and the gonorrhea drug is a jab at AD for not being married anymore? Did I interpret correctly

Zoliflocidan... now I know why Denner was interested in Innoviva...

At any rate, there is probably another play Denner might make with INVA and AMRN. Although my price prediction last year might have been a little high... #418802. He'll probably have his board slam thru a convertible debt note for him first so he gets a bigger slice if the deal goes thru.

hayward, so Cantor Fitz is one of the prime broker accounts. Prime broker divisions are money machines for the clearing firms of the parent brokerage firm. It doesn't make sense that Denner would issue buy orders with competing firms. Cantor is the prime broker of record.
There's absolutely no reason why a firm would short a .50 cent stock risk reward is not worth it. Keep in mind the stock price doesn't reflect the intrinsic value of the company. The company needs to show some growth albeit slow but as I've said many times. The EU endeavor is like a start-up company with $300 mill in the bank and many yrs of proven results for V indication for CVD.

proliberty, actually I happen to have a 2021 13F filing for sarissa cap. They owned INVA 110,520 way back in 11/2021. I haven't run a more recent filing but I'm sure Denner knows the company very well.

proliberty, I just noticed the blocks after hrs. Some dirtbag printed 20 sh trade @ .5161. Should be interesting tomorrow if we continue the upward trend. My 40 day resistance number shows .58 cents.👍️

Lizzy, not sure but 80k trading in after hours so far and see at least 3 10k blocks at $0.5284 as of 5:52pm. Edited - now a 46k block at $0.5284 as well (time stamped 5:41pm).

I'm here but refuse to do the bit until we're back in a more respectable neighborhood. Feel free to take it over, but we warned it comes with a jinx curse.

Ex. There is a change in formulation for Vascepa 2.0 isn't there ? . FDA would definitely want to see if there was any increase in Afib .
JMO
Kiwi

Where’s MRM?

You are correct. Basically take all the gains for the year, subtract the losses, and if the losses are more than the gains then you have a capital loss, whereas if you have more gains than losses (totals) then you have a gain. Unfortunately Uncle Sam will only allow you to deduct 3K of losses in any given year on line 7 of form 1040, whereas there is no such limitation on your gains.

So in your example, 10K gains, 23K losses, means that on line 7 you would enter -3,000 and then carryover the remaining 10K loss to the following year.

Forgot to mention that when you match your losses vs your gains for the year, you would also include any carryover losses from the prior year into the calculation.